Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900292 | 1.00 | FADS1 (0.47) | FADS1SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL2901954 | 0.89 | FADS1 (0.51) | FADS1SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL2901957 | 0.89 | FADS1 (0.51) | FADS1SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL2893545 | 0.88 | FADS1 (0.47) | FADS1SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL2893548 | 0.88 | FADS1 (0.47) | FADS1SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL2901775 | 0.83 | DRD2 (0.45) | FADS1SIGMAR1DRD4 | |
| SCHEMBL2901778 | 0.83 | DRD2 (0.45) | FADS1SIGMAR1DRD4 | |
| SCHEMBL2898927 | 0.81 | CNR2 (0.50) | FADS1HCRTR1HCRTR2 | |
| SCHEMBL2898924 | 0.81 | CNR2 (0.50) | FADS1HCRTR1HCRTR2 | |
| SCHEMBL13086217 | 0.81 | KDM4E (0.45) | FADS1DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| EP-1994016-A2 | 5-PHENYL-3-BENZYL-OXAZOLIDIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | claimed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | FADS1 4353/4885SIGMAR1 175/4885TMEM97 265/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | FADS1 4353/4885SIGMAR1 175/4885TMEM97 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.